Table 1.
Basic Characteristics of Patients Before and After Propensity Matching.
| Before Matching | After Matching | ||||||
|---|---|---|---|---|---|---|---|
| Overall (N = 897) | Protamine full dose (N = 706) | Protamine half dose (N = 191) | p-Value | Protamine full dose (N = 130) | Protamine half dose (N = 130) | p-Value | |
| Median age (IQR)—year | 82 (78–85) | 81 (78–85) | 82 (79–85) | 0.481 | 80 (77–84) | 82 (78–85) | 0.065 |
| Male—no. (%) | 440 (49.1) | 329 (46.6) | 111 (58.1) | 0.005 | 78 (60.0%) | 78 (60.0%) | 1.000 |
| Median logistic EuroSCORE (IQR)—% | 15 (10–23) | 14.5 (10–22) | 18 (11.4–26) | 0.015 | 15.6 (9.6–23.0) | 15.2 (10.5–25.5) | 0.54 |
| COPD—no. (%) | 301 (33.3) | 244 (34.4) | 59 (30.1) | 0.225 | 42 (32.3%) | 44 (33.8%) | 0.301 |
| Diabetes mellitus—no. (%) | 320 (35.7) | 242 (36.1) | 84 (44) | 0.013 | 57 (43.8%) | 44 (33.8%) | 0.098 |
| Hypertension—no. (%) | 709 (79.1) | 560 (79.3) | 149 (78) | 0.787 | 101 (77.7%) | 98 (76.0%) | 0.742 |
| Peripheral artery disease—no. (%) | 140 (15.6) | 98 (13.8) | 42 (22) | 0.006 | 23 (17.7%) | 35 (27.1%) | 0.068 |
| Cerebral artery disease—no. (%) | 273 (30.5) | 207 (29.2) | 67 (35) | 0.121 | 51 (39.2%) | 45 (34.6%) | 0.441 |
| Smoker—no. (%) | 101 (11.3) | 75 (10.6) | 26 (13.6) | 0.246 | 18 (13.8%) | 16 (12.3%) | 0.713 |
| Previous Stroke—no. (%) | 100 (11.1) | 79 (11.1) | 21 (11) | 0.590 | 18 (13.8%) | 18 (13.8%) | 1.000 |
| Median GFR (IQR)—mL/min/1.73 m2 | 56.7 (41–73) | 57 (41–74) | 55.5 (39–69) | 0.757 | 57 (41–71) | 53 (38–69) | 0.527 |
| Median LDL (IQR)—mg/dL | 84 (66–110) | 86.5 (67–112) | 80 (62–101.5) | 0.901 | 85 (63–110) | 78 (61–100) | 0.135 |
| Median Hemoglobin (IQR)—g/dL | 11.9 (11–13) | 11.9 (11–13) | 11.8 (10.3–13) | 0.06 | 12.3 (11.2–13.7) | 11.9 (10.3-13.3) | 0.024 |
| Previous aortic valve replacement—no. (%) | 27 (3) | 23 (3.2) | 4 (2.1) | 0.404 | 3 (2.3%) | 4 (3.1%) | 0.709 |
| Coronary heart disease (CHD)—no. (%) | 609 (67.8) | 420 (59.5) | 189 (100) | <0.001 | 99 (76.2%) | 127 (97.7%) | <0.001 |
| Previous CABG—no. (%) | 83 (9.2) | 71 (10) | 12 (6.3) | 0.11 | 11 (8.5%) | 11 (8.5%) | 1.000 |
| Dual-antiplatelet therapy—no. (%) | 157 (17.5) | 48 (6.8) | 109 (57.1) | <0.001 | 48 (36.9%) | 48 (36.9%) | 1.000 |
| NOAC or VKA—no. (%) | 357 (39.8) | 269 (38.2) | 70 (36.6) | 0.693 | 52 (40.0%) | 42 (32.3%) | 0.197 |
| Indication for NOAC or VKA | <0.001 | ||||||
| Atrial fibrillation—no. (%) | 140 (81.3) | 88 (24.8) | 52 (45.5) | ||||
| Other—no. (%) | 307 (118.7) | 267 (75.2) | 40 (43.5) | ||||
| Concomitant PCI—no. (%) | 60 (31.4) | ||||||